Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses lessons learned about the Biologics Price Competition and Innovation Act in the year following Sandoz v Amgen.
Transcript:
It’s been just about 1 year since Sandoz v Amgen was decided by the Supreme Court. What have we learned since then about the Biologics Price Competition and Innovation Act (BPCIA)?
After Sandoz v Amgen, there were significant concerns that many biosimilar applicants would provide 180-day notice of marketing the day an aBLA, or an Abbreviated Biologics Licence Application, was filed, and that an immediate [declaratory judgment, DJ] action would be filed right after that, so you’d just aboid the BPCIA patent dance and thus completely flout Congressional intent.
But here we are about a year later, and fears of chaos have not yet been realized. According to the data we have collected for BiologicsHQ, only 2 biosimilar manufacturers have so far refused to participate in the patent dance, and one of them still provided their aBLA. Only twice has a biosimilar manufacturer, in the middle of the patent dance, given the 180-day notice of commercial marketing and subsequently filed a DJ action that same day without completing the patent dance. And, in both of those cases, the DJ action was ultimately dismissed.
Really, what we’ve seen is that for the most part, at least with respect to the biologics cases that have been filed since Sandoz v Amgen, companies are choosing to at least start the BPCIA patent dance proceeding, and generally have followed through with most of it. Usually when it hasn’t been completed it was at the negotiation stage when the parties are trying to determine the number of patents to litigate in the first round of the litigation.
We also haven’t seen a lot of issues with federal law not giving the ability to compel production of an aBLA, as there has only been once instance where the biosimilar manufacturer has refused to give the innovator access to their aBLA.
We also have seen that companies generally aren’t launching at-risk. Out of the 11 biosimilars that have been approved so far*, only 3 have launched at-risk.
So, the bottom line is that there hasn’t been as much of an impact as we expected, but that certainly doesn’t mean things won’t change in the future.
*as of the time of filming
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.